


Pre-Commercial Value Assessment of a Nuclear Medicine Theranostic Pair to Diagnose and Treat Neuroendocrine Tumors (NET)

Our client, a **leading radiopharmaceutical company**, needed support to understand the **commercial opportunity** represented by a **Phase III radiopharmaceutical** and its diagnostic radiotracer companion. To understand the dimensions of this commercial opportunity, Alira Health's multidisciplinary team ran a **comprehensive analysis** of the **market characteristics**, the **competitive landscape** of the two assets, the **value proposition** of the assets, and **their value**.


1. RESEARCH MARKET OVERVIEW, DISEASE SEGMENTATION, AND PATIENT POOL



2. UNDERSTAND THE COMPETITIVE LANDSCAPE



3. DETERMINE THE RISK-ADJUSTED NET PRESENT VALUE (rNPV)



Alira Health's multidisciplinary teams, consolidate methodologies, and team of experts can help you understand **the market landscape, highlight risks and opportunities, and assess your target's asset opportunity.**



Please contact us for more information

Piergiulio Lauriano
Partner

piergulio.lauriano@alirahealth.com

www.alirahealth.com